Patrick Brannelly is the founding CEO of the 10,000 Brains Project, a philanthropic initiative that supports the ethical and inclusive use of AI in the development of better treatments for Alzheimer's disease and other neurodegenerative disorders. He has nearly 20 years of experience building groundbreaking neuroscience initiatives.
Most recently, Pat was a member of the Health & Life Sciences team at Gates Ventures, where he served as the Director of Partnerships & Business Development for the Alzheimer’s Disease Data Initiative. Prior to this, he was the Managing Director of the Rainwater Charitable Foundation’s Tau Consortium, which seeks to accelerate the development of new treatments for Alzheimer’s disease and frontotemporal dementia.
Earlier in his career, Pat was the co-founder and CEO of NeoCORTA and the Director of Partnerships & Group Programs at Posit Science, both early-stage brain health technology ventures. He has also served in the US and Europe as a management consultant in the pharmaceutical, energy, and technology sectors. He is a former Assistant Professor of entrepreneurship and strategy at California State University, Fresno.
Pat holds a BA in Psychology from Harvard College, an MBA with Distinction from Harvard Business School, and an MSc in Applied Neuroscience with Distinction from King’s College London. At King's, his dissertation explored the feasibility of using microRNA biomarkers to enable a precision medicine approach in the treatment of Alzheimer’s disease. A list of his scientific publications can be found on ORCID and Google Scholar.
A frequent member of boards and steering committees, Pat currently serves as a Board member of Stroke Onward. He is an advisor on two upcoming documentaries about Alzheimer's disease, and an active advisor to several early-stage neuroscience ventures.
In recent years, Pat has also served on the Boards of the FTD Disorders Registry, the Alzheimer's Association National Capital Chapter, and the OECD's Neuroscience-Inspired Policy Initiative. In 2019, he served on the Steering Commitee that drafted the NIH's 3-year funding priorities for Alzheimer's and related dementias.
Sign up to hear about news, views, and events.
We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.